Plasminogen activator inhibitor 1: The two faces of the same coin

Current Opinion in Nephrology and Hypertension

Volumn 13, Issue 1, 2004, Pages 39-44

  Hertig, Alexandre ^b   Rondeau, Eric ^a  

^a INSERM   (France)

^b NONE

Author keywords

Atherosclerosis; Plasmin; Plasminogen activator inhibitor 1; Transforming growth factor beta

Indexed keywords

FIBRIN; PLASMIN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; VITRONECTIN;

ALLERGIC GLOMERULONEPHRITIS; AORTA ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BINDING SITE; BLOOD VESSEL WALL; CELL ADHESION; CELL MIGRATION; CELL PROTECTION; EXTRACELLULAR MATRIX; FIBRIN DEPOSITION; FIBRIN FORMATION; FIBRINOLYSIS; FIBROGENESIS; FIBROSIS; HUMAN; IN VITRO STUDY; INFLAMMATION; KIDNEY DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SMOOTH MUSCLE FIBER;

ANIMALS; ARTERIOSCLEROSIS; EXTRACELLULAR MATRIX; FIBRINOLYSIS; HUMANS; KIDNEY; KIDNEY DISEASES; MUSCLE, SMOOTH, VASCULAR; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENAL CIRCULATION;

EID: 1642268701     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200401000-00006     Document Type: Review

References (29)

1. Rerolle JP, Hertig A, Nguyen G, et al. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int 2000; 58:1841-1850.
2. Eddy A. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol 2002; 283:F209-F220. An extensive and comprehensive review of the potential role of PAI-1 during acute and chronic renal diseases.
3. Dewerchin M, Collen D, Lijnen HR. Enhanced fibrinolytic potential in mice with combined homozygous deficiency of alpha2-antiplasmin and PAI-1. Thromb Haemost 2001; 86:640-646. In this study, the absence of PAI-1 did not influence the amount of fibrin deposited in the kidneys after endotoxin injection, questioning the importance of PAI-1 regarding the surveillance of intra-renal fibrinolysis.
4. Kitching AR, Kong YZ, Huang XR, et al. Plasminogen activator inhibitor-1 is a significant determinant of renal injury in experimental crescentic glomerulonephritis. J Am Soc Nephrol 2003; 14:1487-1495. A study in which the intensity of the fibrin deposits in the glomerular tuft and the infiltration by leukocytes are directly correlated with the PAI-1 gene dosage, suggesting that PAI-1 could play a major, negative role in glomerular fibrinolysis and inflammation.
5. Hertig A, Berrou J, Allory Y, et al. Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through TGF-beta overactivation. FASEB J 2003; 17:1904-1906. In this study, the absence of PAI-1 paradoxically exacerbated the course of passive, anti-GBM glomerulonephritis, and enhanced fibrin deposition, by a mechanism that involved the regulation of the activation of TGF-β by plasminogen activators, independently of plasmin.
6. Drew AF, Tucker HL, Liu H, et al. Crescentic glomerulonephritis is diminished in fibrinogen-deficient mice. Am J Physiol 2001; 281:F1157-F1163.
7. Patterson C, Stouffer GA, Madamanchi N, Runge MS. New tricks for old dogs: non thrombotic effects of thrombin in vessel wall biology. Circ Res 2001; 88:987-997.
8. van Meijer M, Smilde A, Tans G, et al. The suicide substrate reaction between plasminogen activator inhibitor 1 and thrombin is regulated by the cofactors vitronectin and heparin. Blood 1997; 90:1874-1882.
9. Kanamaru Y, Nakao A, Mamura M, et al. Blockade of TGF-β signaling in T cells prevents the development of experimental glomerulonephritis. J Immunol 2001; 166:2818-2823.
10. Zhou A, Ueno H, Shimomura M, et al. Blockade of TGF-beta ameliorates renal dysfunction and histologic progression in anti-GBM nephritis. Kidney Int 2003; 64:92-101. In this study, the systemic blockade of TGF-β by specific gene therapy improved the outcome of anti-GBM nephritis.
11. Eitzman DT, McCoy RD, Zheng X, et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97:232-237.
12. Hattori N, Degen JL, Sisson TH, et al. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest 2000; 106:1341-1350.
13. Kaikita K, Fogo AB, Ma L, et al. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation 2001; 104:839-844.
14. Oda T, Jung YO, Kim HS, et al. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 2001; 60:587-596.
15. Huang Y, Haraguchi M, Lawrence DA, et al. A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest 2003; 112:379-388. The first study to demonstrate that therapeutic intervention with PAI-1 inhibitors may reduce glomerular fibrosis, by competing with endogenous PAI-1.
16. Edgtton KL, Carmeliet P, Kitching AR. Endogenous plasmin is not protective in unilateral ureteric ligation induced renal interstitial fibrosis [Abstract]. Am Soc Nephrol 2002; 13:539A.
17. Marshall LJ, Ramdin LS, Brooks T, et al. Plasminogen activator inhibitor-1 supports IL-8-mediated transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes. J Immunol 2003; 171:2057-2065. In an original approach, the authors report that PAI-1 is involved in the stabilization of a mediator of inflammation, by a plasmin-dependent mechanism.
18. Yang J, Shultz RW, Mars WM, et al. Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest 2002; 110:1525-1538. Unexpectedly, the absence of tPA is shown to play a protective role during UUO. Originally, the authors demonstrated that tPA induces matrix metalloproteinase 9 gene expression by renal interstitial fibroblasts, and promotes epithelial-to-myofibroblast transition.
19. Zhang G, Kim HS, Cai X, et al. Urokinase receptor deficiency accelerates renal fibrosis in obstructive nephropathy. J Am Soc Nephrol 2003; 14:1254-1271. uPAR is shown to lower renal fibrosis in the UUO model, by a mechanism that could involve the activation of hepatocyte growth factor by uPA.
20. ••].
21. Carmeliet P, Moons L, Lijnen HR, et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation. Circulation 1997; 96:3180-3191.
22. DeYoung MB, Tom C, Dichek DA. Plasminogen activator inhibitor-1 increases neointima formation in balloon-injured rat carotid arteries. Circulation 2001; 104:1972-1981.
23. Sobel B. Increased plasminogen activator inhibitor-1 and vasculopathy: a reconcilable paradox. Circulation 1999; 99:2496-2498. An elegant discussion, in which the author discusses the contradictory findings reported on the impact of PAI-1 expression in vivo during atherosclerotic disease.
24. Loskutoff DJ, Quigley JP. PAI-1, fibrosis, and the elusive provisional fibrin matrix. J Clin Invest 2000; 106:1441-1443.
25. Xiao Q, Danton MJ, Witte DP, et al. Fibrinogen deficiency is compatible with the development of atherosclerosis in mice. J Clin Invest 1998; 101:1184-1194.
26. Sjöland H, Eitzman DT, Gordon D, et al. Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 2000; 20:846-852.
27. Luttun A, Lupu F, Storkebaum E, et al. Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2002; 22:499-505. The paradoxically protective role of PAI-1 is reported in a model of accelerated vascular fibrosis. The absence of PAI-1 results in the deposition of a chaotic matrix and in the overactivation of TGF-β (this is the first demonstration in vivo).
28. Eitzman DT, Westrick RJ, Xu Z, et al. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 2000; 96:4212-4215.
29. Eren M, Painter CA, Atkinson JB, et al. Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 2002; 106:491-496. A key study, demonstrating that PAI-1 is critically involved in the pathogenesis of coronary atherosclerosis, and in which PAI-1-overexpressing mice die of myocardial stroke.